Cholesterol medications lower the amount of cholesterol circulating in your blood, primarily by changing how your liver produces or processes it. The most commonly prescribed type, statins, can reduce LDL (“bad”) cholesterol by 30% to 50%, and most of that drop happens within the first two weeks of treatment. But statins aren’t the only option. Several different classes of cholesterol drugs exist, each working through a distinct mechanism, and understanding what they do can help you make sense of your treatment plan.
How Statins Lower Cholesterol
Statins are the most widely prescribed cholesterol medications in the world, and they work by targeting your liver directly. Your liver manufactures most of the cholesterol in your body through a multi-step process. Statins block a specific enzyme that controls the pace of that process, essentially putting the brakes on your liver’s cholesterol production line.
What happens next is equally important. When your liver cells sense they have less cholesterol available internally, they respond by pulling more LDL cholesterol out of your bloodstream. They do this by increasing the number of receptors on their surface that grab onto LDL particles floating past. So statins work in two ways at once: they reduce how much cholesterol your liver makes and increase how much it removes from your blood.
About 90% of the maximum LDL reduction shows up within two weeks of starting treatment, based on clinical trial data. Your doctor will typically recheck your levels after four to six weeks to confirm the medication is working as expected.
Cholesterol Absorption Blockers
Not all cholesterol in your blood comes from your liver. Some comes from the food you eat, absorbed through the lining of your small intestine. Ezetimibe, the main drug in this class, works by blocking a specific protein on the surface of intestinal cells that acts as a gateway for cholesterol. Without that gateway functioning normally, cholesterol from your diet stays trapped on the outer surface of the intestinal cells instead of being pulled inside and sent into your bloodstream.
Ezetimibe is often prescribed alongside a statin because the two drugs attack cholesterol from completely different angles. The statin reduces production in the liver while ezetimibe blocks absorption in the gut. Together, they can achieve a larger LDL reduction than either drug alone.
PCSK9 Inhibitors
These are injectable medications typically reserved for people whose cholesterol remains too high on statins alone, or who can’t tolerate statins at all. They work by protecting the LDL receptors on your liver cells.
Here’s the problem they solve: your liver cells have receptors that pull LDL cholesterol out of your blood, but a protein called PCSK9 tags those receptors for destruction. When PCSK9 binds to a receptor, the receptor gets broken down inside the cell instead of being recycled back to the surface to grab more LDL. PCSK9 inhibitors are antibodies that block PCSK9 from attaching to those receptors. With more receptors surviving and returning to the cell surface, your liver clears LDL from the blood much more efficiently. These drugs can lower LDL by 50% to 60% on top of what statins already achieve.
Fibrates Target Triglycerides
Statins are effective at lowering LDL, but they don’t do much for triglycerides, another type of fat in your blood that raises cardiovascular risk when elevated. Fibrates fill that gap. They activate a set of cellular switches in the liver that reduce the raw materials available for triglyceride production. They also speed up the breakdown of triglyceride-rich particles already circulating in your blood by boosting the activity of an enzyme that breaks them apart.
As a bonus, fibrates raise HDL (“good”) cholesterol by increasing production of the proteins that form HDL particles. They’re sometimes prescribed alongside statins for people who have high triglycerides in addition to high LDL.
Bempedoic Acid for Statin Intolerance
Bempedoic acid is a newer cholesterol-lowering drug that works in the liver through a different pathway than statins. It blocks an enzyme involved earlier in the cholesterol production chain, which ultimately has a similar downstream effect: less cholesterol made in the liver, more LDL receptors put on the surface, more LDL cleared from the blood. At a standard dose, it lowers LDL by roughly 30%.
The key advantage is what it doesn’t do. Bempedoic acid is a “pro-drug,” meaning it needs to be converted into its active form inside liver cells by an enzyme that exists only in the liver, not in muscle tissue. Because the drug never activates in your muscles, it avoids the muscle-related complaints that lead some people to stop taking statins. Clinical trials in statin-intolerant patients showed no increase in muscle aches or weakness compared to placebo.
How Much These Drugs Reduce Heart Risk
Lowering your LDL number matters because it translates into fewer heart attacks and strokes. A large meta-analysis by the Cholesterol Treatment Trialists’ Collaboration found a consistent 20% relative reduction in major cardiovascular events for every 1 mmol/L (roughly 39 mg/dL) drop in LDL cholesterol, regardless of how high or low your starting risk was. That means the benefit scales with how much your LDL decreases: a bigger drop yields more protection.
This benefit applies across medication classes. Whether your LDL goes down because of a statin, ezetimibe, a PCSK9 inhibitor, or some combination, the reduction in cardiovascular events per unit of LDL lowering is remarkably similar. What your body cares about is the LDL level itself, not which drug got it there.
The Muscle Pain Question
Muscle aches are the most common reason people stop taking statins, reported by roughly 60% of those who quit. But the relationship between statins and muscle symptoms is more complicated than it appears. A revealing crossover trial published in the Journal of the American College of Cardiology gave patients alternating months of a statin, a placebo, and no pill at all. Symptom scores were significantly higher during statin months than during no-pill months, but they were almost identically high during placebo months. The difference between statin and placebo was not statistically significant.
Participants stopped their statin months early 21.6% of the time, and stopped their placebo months early 17.2% of the time, a gap that was also not statistically significant. This suggests that a large portion of muscle symptoms attributed to statins are driven by the expectation of side effects (the “nocebo effect”) rather than the drug’s chemistry. That said, true statin-related muscle problems do occur in a small percentage of patients, which is partly why alternatives like bempedoic acid were developed.
When Medication Is Recommended
Current guidelines from the American College of Cardiology and American Heart Association use a tiered approach. If you’ve already had a heart attack, stroke, or other cardiovascular event, high-intensity statin therapy is the standard recommendation, with additional drugs considered if your LDL stays above 70 mg/dL.
For people without existing heart disease, the thresholds depend on your situation. An LDL of 190 mg/dL or higher calls for statin therapy regardless of other factors, because levels that high carry substantial long-term risk on their own. Adults aged 40 to 75 with diabetes generally start a moderate-intensity statin when their LDL is 70 mg/dL or above. For everyone else in that age range, the decision weighs your 10-year risk of a cardiovascular event alongside your LDL level, and the conversation with your doctor becomes more nuanced.